Elsevier

Neuropharmacology

Volume 34, Issue 10, October 1995, Pages 1297-1303
Neuropharmacology

General paper
The interactions of typical and atypical antipsychotics with the (−)2,5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus

https://doi.org/10.1016/0028-3908(95)00101-BGet rights and content

Abstract

The present study was designed to test the hypothesis that atypical, but not typical, antipsychotics produce a functional in vivo blockade of 5-HT2A receptors. The magnitude of functional in vivo 5-HT2A receptor blockade elicited by representative compounds from each of the six major structural classes of typical antipsychotics, and the representative atypical antipsychotics clozapine and risperidone, was indicated by their respective abilities to block the stimulus effects of the phenylalkylamine hallucinogen (−)DOM in the rat. Chlorpromazine, thioridazine, fluphenazine, thiothixene and haloperidol did not produce a significant antagonism of the (−)DOM stimulus. The benzoxapine, loxapine (60%), and the atypical dibenzodiazepine, clozapine (62%), partially blocked and risperidone fully blocked (100%) the (−)DOM stimulus. None of these agents elicited significant levels of (−)DOM-appropriate responding when administered alone. These results indicate that the typical antipsychotics, with the exception of lozapine, fail to produce effective in vivo antagonism of 5-HT2A receptors at doses compatible with the preservation of operant behavior. In contrast, the atypical antipsychotics clozapine and risperidone elicit effective in vivo antagonism of 5-HT2A receptors without severe behavioral disruption. Thus, these data are supportive of the hypothesis that the mechanism of action of atypical, but not typical, antipsychotics involves the antagonism of 5-HT2A receptors in vivo.

References (44)

  • A. Carlsson et al.

    Effect of chlorpromazine and haloperidol on formation of 3-methoxytryptamine and normetanephrine in mouse brain

    Acta Pharmac. Toxic.

    (1963)
  • D.E. Casey et al.

    Neuroleptic side effects: acute extrapyramidal symptoms and tardive dyskinesia

  • A. Claus et al.

    Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study

    Acta Psychiatr. Scand.

    (1992)
  • L. Farde et al.

    Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

    Arch. Gen. Psychiat.

    (1992)
  • D. Fiorella et al.

    The time dependent stimulus effects of (−)2,5- dimethoxy-4-methylamphetamine: Implications for drug- induced stimulus control as a method for the study of hallucinogenic drugs

    Psychopharmacology

    (1995)
  • D. Fiorella et al.

    The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis

    Psychopharmacology

    (1995)
  • D. Fiorella et al.

    The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: Reassessment of LSD false positives

    Psychopharmacology

    (1995)
  • D. Fiorella et al.

    5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine

    Psychopharmacology

    (1995)
  • R.L. Freidman et al.

    Clozapine blocks the disruptive and discriminative effects of quipazine

    Eur. J. Pharmac.

    (1985)
  • Y.G. Gelders et al.

    Serotonin-S2 blockers in the treatment of chronic schizophrenia

    Clin. Neuropharmac.

    (1986)
  • R.C. Heel et al.

    Loxapine: a review of its pharmacological properties and therapeutic efficacy as a antipsychotic agent

    Drugs

    (1978)
  • A.M. Ismaiel et al.

    Antagonism of the l-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist

    J. Med. Chem.

    (1993)
  • Cited by (0)

    View full text